A Study of DF6002 Alone and in Combination With Nivolumab
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Dragonfly Therapeutics
- ID
- NCT04423029
- Phase
- Phase 1/2 Solid Tumor Research Study
- Study Type
- Interventional
- Participants
- Expecting 473 study participants
- Last Updated